Clinical trial
A Comparison of Study Drug With Placebo and Haloperidol in Patients With…
NCT00044044 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00044044 |
|---|---|
| Title | A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia |
| Official title | A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol in Patients With Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo |
| Enrollment | 356 |
| Start date | Jul 1, 2002 |
| Primary completion | May 1, 2003 |
| Completion | May 1, 2003 |
| First posted | Aug 20, 2002 |
| Last update posted | Apr 17, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: